(HealthDay)—Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration to treat patients with metastatic non-small-cell lung cancer (NSCLC) with a specific genetic mutation (epidermal growth factor receptor ...
Jul 14, 2015
0
10
About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make ...
Apr 28, 2022
0
34
Blocking the uptake of large amounts of cholesterol into brain cancer cells could provide a new strategy to battle glioblastoma, one of the most deadly malignancies, researchers at UCLA's Jonsson Comprehensive Cancer Center ...
Sep 15, 2011
0
1
Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, ...
Nov 13, 2011
0
0
The standard treatment for patients with advanced non-small cell lung cancer (NSCLC) is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now, Fox ...
Jun 1, 2011
0
0
Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive ...
Sep 17, 2012
0
0
Two recently approved leukemia drugs could be enlisted against treatment-resistant lung cancer, with a clinical trial expected to launch in Toronto and Zagreb, Croatia, later this year to evaluate one of them.
Feb 24, 2020
0
122
Researchers at VCU Massey Cancer Center discovered a cellular partnership that drives the growth of deadly brain tumors and could potentially serve as a novel target for disease treatment.
Oct 5, 2022
0
42
According to a new study, mortality rates from the most common lung cancer, non-small cell lung cancer (NSCLC), have fallen sharply in the United States in recent years, due primarily to recent advances in treatment.
Aug 12, 2020
0
232
Researchers at the Yale Cancer Biology Institute have clarified the role of a recurring cancer-associated tumor mutation in glioblastoma multiforme (GBM), the most common and most aggressive type of malignant brain tumor. ...
Feb 9, 2022
0
40
